VALUE HEALTH REPLACING LOW-DOSE MEVACOR WITH LESCOL: SANDOZ PRODUCT IS ONE OF NEW BREED OF "MANAGED CARE" PRODUCTS, EXPRESS SCRIPTS PRESIDENT TELLS ANALYSTS
The Value Health formularies will add the Sandoz HMG-CoA reductase inhibitor Lescol in place of the Merck pioneer in the class, Mevacor, to take advantage of Sandoz discount prices, Value Health Chairman Robert Patricelli reported May 10 at Alex. Brown's 19th Annual Health Care Seminar in Baltimore.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth